Immune Design is a clinical stage immunotherapy company employing next-generation in vivo approaches to enable the body’s immune system to fight disease. The company’s technologies are engineered to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells to fight cancer and other chronic diseases. Immune Design’s clinical programs are the product of its two synergistic discovery platforms: ZVexTM and GLAASTM.
Dec 5, 2016
Immune Design Provides Update from Two Discovery Platforms: DC-tropic ZVex Delivering Multiple Tumor Antigens (Conserved and Neo-Antigens) and G100 For Intratumoral Immunotherapy
Nov 11, 2016
New Immune Design Data Highlights Expanded Product Potential of ZVex® Platform at the 2016 SITC Annual Meeting
Nov 16, 2016 at 8:40 AM UK
Nov 9, 2016 at 4:30 PM ET